AI assistant
REGENXBIO Inc. — Director's Dealing 2017
Apr 27, 2017
32827_dirs_2017-04-26_6cd3c944-6d54-4b2c-a58d-a300ac26e0cd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENXBIO Inc. (RGNX)
CIK: 0001590877
Period of Report: 2017-04-24
Reporting Person: Mills Kenneth T. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-04-24 | Common Stock | S | 14045 | $20.94 | Disposed | 126395 | Direct |
| 2017-04-24 | Common Stock | S | 1395 | $21.40 | Disposed | 125000 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2: This transaction was executed in multiple trades at prices ranging from $20.40 to $21.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $21.40 to $21.425. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.